SNN Stock Analysis: Smith & Nephew SNATS | NYSE
Medical Devices | NYSE, USA | Market Cap: 12.784m USD | 12M Return: -3.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.7M
EPS Trend: -9.4%
Qual. Beats: 0
Rev. Trend: 85.8%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Smith & Nephew plc is a UK-headquartered global medical device company founded in 1856 and listed on the NYSE under the ticker SNN. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, serving healthcare providers in the UK, the US, and other international markets.
The Orthopaedics segment supplies knee and hip implants, trauma and extremities devices, and other reconstruction products. The Sports Medicine & ENT segment offers minimally invasive joint repair implants and instruments, arthroscopic visualization and tissue resection technologies, and ear, nose, and throat solutions. The Advanced Wound Management segment provides advanced wound care dressings, bioactives and regenerative medicine products (including skin and bone graft substitutes), and wound therapy devices such as negative pressure wound therapy and hydrosurgery systems.
As a large-cap Health Care Equipment company, Smith & Nephew operates in a sector defined by long product development timelines, stringent regulatory approval processes (such as FDA and CE marking), and demand driven by surgical volumes, an aging population, and the prevalence of chronic wounds. The business model typically relies on selling consumables and implants through hospital and surgical channels, complemented by recurring revenue from wound care products used across both hospital and community care settings.
- Orthopaedics segment pressured by Stryker and Zimmer Biomet pricing
- Sports Medicine and ENT deliver double-digit procedural volume growth
- Advanced Wound Management faces negative pressure wound therapy competition
| Net Income: 626.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.31 > 1.0 |
| NWC/Revenue: 40.59% < 20% (prev 49.74%; Δ -9.15% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.29b > Net Income 626.5m |
| Net Debt (2.99b) to EBITDA (1.58b): 1.89 < 3 |
| Current Ratio: 2.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (436.5m) vs 12m ago -50.03% < -2% |
| Gross Margin: 68.01% > 18% (prev 69.64%; Δ -1.63% > 0.5%) |
| Asset Turnover: 59.38% > 50% (prev 56.11%; Δ 3.26% > 0%) |
| Interest Coverage Ratio: 6.43 > 6 (EBIT TTM 1.01b / Interest Expense TTM 156.4m) |
| A: 0.24 (Total Current Assets 4.10b - Total Current Liabilities 1.59b) / Total Assets 10.5b |
| B: 0.51 (Retained Earnings 5.32b / Total Assets 10.5b) |
| C: 0.10 (EBIT TTM 1.01b / Avg Total Assets 10.4b) |
| D: 1.02 (Book Value of Equity 5.29b / Total Liabilities 5.17b) |
| Altman-Z'' = 4.96 = AAA |
| DSRI: 1.11 (Receivables 1.43b/1.21b, Revenue 6.18b/5.81b) |
| GMI: 1.02 (GM 69.64% / 68.01%) |
| AQI: 1.04 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 1.06 (Revenue 6.18b / 5.81b) |
| TATA: -0.06 (NI 626.5m - CFO 1.29b) / TA 10.5b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 28.81 with a total of 3,803,681 shares traded. Over the past week, the price has changed by -5.06%, over one month by -2.54%, over three months by -10.47% and over the past year by -3.90%.
Current recommended Stop Loss: 28.00 (which is 2.8% or 1.4 ATR below the current price).
Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold SNN.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35 | 21.5% |
P/E Trailing = 21.1329
P/E Forward = 13.6426
P/S = 2.074
P/B = 2.4171
P/EG = 1.2084
Revenue TTM = 6.18b USD
EBIT TTM = 1.01b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 3.03b USD (from longTermDebt, last quarter)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 216.0m
Net Debt = 2.99b USD (calculated: Debt 3.54b - CCE 557.0m)
Enterprise Value = 15.8b USD (12.8b + Debt 3.54b - CCE 557.0m)
Interest Coverage Ratio = 6.43 (Ebit TTM 1.01b / Interest Expense TTM 156.4m)
EV/FCF = 18.47x (Enterprise Value 15.8b / FCF TTM 854.0m)
FCF Yield = 5.42% (FCF TTM 854.0m / Enterprise Value 15.8b)
FCF Margin = 13.82% (FCF TTM 854.0m / Revenue TTM 6.18b)
Net Margin = 10.14% (Net Income TTM 626.5m / Revenue TTM 6.18b)
Gross Margin = 68.01% ((Revenue TTM 6.18b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.51 (Enterprise Value 15.8b / Total Assets 10.5b)
Interest Expense / Debt = 4.41% (Interest Expense 156.4m / Debt 3.54b)
Taxrate = 19.77% (154.4m / 780.8m)
NOPAT = 806.6m (EBIT 1.01b * (1 - 19.77%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.67 (Debt 3.54b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 1.89 (Net Debt 2.99b / EBITDA 1.58b)
Debt / FCF = 3.50 (Net Debt 2.99b / FCF TTM 854.0m)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 626.5m / Total Assets 10.5b)
RoE = 11.77% (Net Income TTM 626.5m / Total Stockholder Equity 5.32b)
RoCE = 12.04% (EBIT 1.01b / Capital Employed (Equity 5.32b + L.T.Debt 3.03b))
RoIC = 9.27% (NOPAT 806.6m / Invested Capital 8.70b)
WACC = 5.65% (E(12.8b)/V(16.3b) * Re(6.23%) + D(3.54b)/V(16.3b) * Rd(4.41%) * (1-Tc(0.20)))
Discount Rate = 6.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -22.47 | Cagr: -26.39%
[DCF] Terminal Value 77.97% ; FCFF base≈754.8m ; Y1≈865.2m ; Y5≈1.27b
[DCF] Fair Price = 38.24 (EV 19.2b - Net Debt 2.99b = Equity 16.2b / Shares 423.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -9.43 | EPS CAGR: -6.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: 85.76 | Revenue CAGR: 13.97% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.95 | Chg30d=N/A | Revisions=+20% | GrowthEPS=-4.6% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=2.16 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+10.9% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: +20%